Jazz Pharmaceuticals (JAZZ) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Which has more risk and volatility, JAZZ or RPRX?

Jazz Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Is JAZZ or RPRX more profitable?

Royalty Pharma has a net margin of 37.94% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.60%	29.30%	9.72%
Royalty Pharma	37.94%	24.40%	14.01%

Does the media prefer JAZZ or RPRX?

In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 16 mentions for Royalty Pharma. Jazz Pharmaceuticals' average media sentiment score of 1.38 beat Royalty Pharma's score of 1.12 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	17 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of JAZZ or RPRX?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, JAZZ or RPRX?

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.06B	1.65	$414.83M	$7.50	14.49
Royalty Pharma	$2.26B	8.24	$858.98M	$1.85	17.49

Do analysts prefer JAZZ or RPRX?

Jazz Pharmaceuticals currently has a consensus price target of $182.79, indicating a potential upside of 68.14%. Royalty Pharma has a consensus price target of $42.50, indicating a potential upside of 31.32%. Given Jazz Pharmaceuticals' higher probable upside, research analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer JAZZ or RPRX?

Jazz Pharmaceuticals received 816 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.83% of users gave Jazz Pharmaceuticals an outperform vote while only 67.98% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Jazz Pharmaceuticals	Outperform Votes 1143 80.83%	Underperform Votes 271 19.17%
Royalty Pharma	Outperform Votes 327 67.98%	Underperform Votes 154 32.02%

Summary

Jazz Pharmaceuticals beats Royalty Pharma on 10 of the 19 factors compared between the two stocks.